Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06056297 · ClinicalTrials.gov registry record · Phase 3
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
A Phase 3 study of Neutropenia, sponsored by X4 Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 176
- Enrollment target
- 20
- Study locations
NCT06056297: Recruiting Phase 3 study of Neutropenia, sponsored by X4 Pharmaceuticals.
NCT06056297 is a Phase 3 study of Neutropenia that is actively recruiting participants, run by X4 Pharmaceuticals. The registered enrollment target is 176 participants, above the 63-participant average among 12 other Neutropenia trials with a reported enrollment target (179% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06056297, a Phase 3 study of Neutropenia, is actively recruiting participants, sponsored by X4 Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 176 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to demonstrate the efficacy and evaluate the safety and tolerability of mavorixafor in participants with congenital or acquired primary autoimmune and idiopathic chronic neutropenic disorders who are experiencing recurrent and/or serious infections as assessed by demonstrating its clinical benefit and increasing levels of circulating neutrophils.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Mavorixafor
Study Locations (20)
California
- UC Irvine - Irvine
- Orso Health - La Jolla
- University of California, Los Angeles-UCLA - Los Angeles
- Orso Health - Torrance
Texas
- UT Southwestern Medical Center - Dallas
- Cook Children's Medical Center - Fort Worth
- Texas Children's Hospital/ Baylor College of Medicine - Houston
- Sarah Cannon Research Institute - Woodland
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
- Cleveland Clinic - Cleveland
Arizona
- Phoenix Children's Hospital - Phoenix
Florida
- University of Southern Florida - St. Petersburg
Georgia
- Children's Healthcare of Atlanta (CHOA) - Atlanta
Iowa
- University of Iowa - Iowa City
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 176 participants |
| Start Date | 2024-06-06 |
| Est. Completion | 2027-11 |
| Phase | Phase 3 |
What NCT06056297 shows while recruiting
NCT06056297 is an interventional study that assigns participants to a tested intervention. The registered 176 participants enrollment target is mid-sized for trials with a published cap, above the 63-participant average among 12 other Neutropenia trials with a reported enrollment target (179% higher).
The record links to 1 condition, with Neutropenia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06056297 names 20 study sites across 13 states, led by California, Texas, Ohio.
Frequently Asked Questions
What is clinical trial NCT06056297 about?
NCT06056297 is a clinical study titled "A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections". The purpose of this study is to demonstrate the efficacy and evaluate the safety and tolerability of mavorixafor in participants with congenital or acquired primary autoimmune and idiopathic chronic neutropenic disorders who are experiencing recurrent and/or serious infections as assessed by demonst...
What is the current status of trial NCT06056297?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 176 participants. The study started on 2024-06-06. Estimated completion is 2027-11.
What conditions does trial NCT06056297 study?
This clinical trial studies the following conditions: Neutropenia.
What interventions are being tested in trial NCT06056297?
The interventions under investigation include: Placebo (DRUG), Mavorixafor (DRUG).
Who is sponsoring clinical trial NCT06056297?
This trial is sponsored by X4 Pharmaceuticals, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06056297 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neutropenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06056297's enrollment target sits among peer trials
176 2nd of 12 the highest of 12 other Neutropenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neutropenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Prospective, Randomized, Phase III Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) Versus PIXY 321 in Advanced Breast Cancer
COMPLETED · Phase 3
-
Safety and Effectiveness of Granulocyte Transfusions in Resolving Infection in People With Neutropenia (The RING Study)
COMPLETED · Phase 3
-
Voriconazole vs. Amphotericin B in the Treatment of Invasive Aspergillosis
COMPLETED · Phase 3
-
Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia
RECRUITING · Phase 2
-
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
RECRUITING · Phase 1
-
Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03304821 · 176 participants · Phase 2
Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease
- NCT03447938 · 176 participants · NA
The Minimally Invasive Coronary Surgery Compared to STernotomy Coronary Artery Bypass Grafting Trial
- NCT03824145 · 176 participants · NA
Every Day Counts: A Lifestyle Program for Women With Metastatic Breast Cancer
- NCT04177914 · 176 participants · Phase 3
HCRN Endoscopic Versus Shunt Treatment of Hydrocephalus in Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI